StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the stock.
Moleculin Biotech Price Performance
Shares of Moleculin Biotech stock opened at $2.55 on Friday. The business’s fifty day simple moving average is $2.49 and its 200-day simple moving average is $3.54. Moleculin Biotech has a 52 week low of $2.12 and a 52 week high of $15.75.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.13). As a group, sell-side analysts expect that Moleculin Biotech will post -8.6 EPS for the current year.
Institutional Inflows and Outflows
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Further Reading
- Five stocks we like better than Moleculin Biotech
- Most Volatile Stocks, What Investors Need to Know
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Use the MarketBeat Dividend Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.